The Incit teams

Team 3

Anti-tumour immunosurveillance and immunotherapy 

EQ3 photo insert

Objectives of the research programs

Our projects aim to elucidate the mechanisms involved in the regulation of immune responses in human solid tumours, to identify new therapeutic targets, to develop and optimise anti-tumor and anti-viral immunotherapy strategies, and to identify early markers of response to these treatments.

 

Research projects

Our work is organised around 4 main interrelated programs focusing on

  1. The characterization of anti-tumour T responses in solid tumors (melanoma and colorectal cancer), as well as their regulation within the tumour microenvironment, notably by immune checkpoint signalling pathways, and certain innate immunity pathways including the inflammasome of tumor cells. Coordinated by N. Gervois, A. Jarry, H. Benlalam, F. Davodeau.
  2. The characterization of tumour-specific antigens derived from mutations, defects in antigen presentation machinery, or alternative tumor-specific translation mechanisms that may constitute new relevant targets for anti-tumour immunotherapy. Coordinated by F. Lang, C. Rabu, N. Gervois.
  3. The development and optimization of immunotherapy strategies, particularly adoptive transfer strategies of T lymphocytes specific for tumor epitopes (from melanoma and colorectal cancer) and viral epitopes (HIV), by optimzing lymphocyte functions using genome editing methods. Coordinated by N. Labarriere and B. Monel
  4. Research and characterization of early markers of response to immunotherapy treatments with immune checkpoint inhibitors. Coordinated by N. Labarriere

Our team is part of the programme of excellenceLabEx IGO(Immunograft-Oncology) and our research programs have been approved by the National League against Cancer(2022-2026)

Graphic summary

Graphical abstract team 3 INCIT

Highlights

Marotte et al. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
J Immunother Cancer, 2020

Logo

Themes addressed

Anti-tumor T cell responses: characterization of immune subpopulations and regulation by the microenvironment
Coordinated by N. Gervois, H. Benlalam, F. Davodeau and A. Jarry

Identification and characterization of target antigens for immunotherapy in melanoma and colorectal cancer
Coordinated by F. Lang, N. Gervois and C. Rabu

Optimization of T cell functions for adoptive cell transfer (Cancer and viral infections).
Coordinated by N. Labarriere and B. Monel

Definition of early cellular markers of response to immunotherapies.
Coordinated by N. Labarriere

The team

3 researchers 

4 teacher-researchers

1 ATER

  • Carolina Nicolau

2 post doc

4 ITA

8 PhD students

    Full organisation chart of the unit

    Find below the global staffing of the unit in pdf format

    Scientific publications

    Find the major publications of the team of the last 2 years

    hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cells.

    Charpentier M, Dupré E, Fortun A, Briand F, Maillasson M, Com E, Pineau C, Labarrière N, Rabu C, Lang F.

    Mol Oncol. 2022 Feb;16(3):594-606. doi: 10.1002/1878-0261.13088.

    Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. 

    Ducoin KOger R, Bilonda Mutala L, Deleine C, Jouand N, Desfrançois J, Podevin J, Duchalais E, Cruard J, Benlalam H, Labarrière N, Bossard C, Jarry A, Gervois-Segain N.

    OncoImmunoly. 2022 Tue 09; doi.org/10.1080/2162402X.2022.2046931

    The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer.

    Mutala LBDeleine C, Karakachoff M, Dansette D, Ducoin K, Oger R, Rousseau O, Podevin J, Duchalais E, Fourquier P, Thomas WEA, Gourraud PA, Bennouna J, Brochier C, Gervois N, Bossard C, Jarry A

    Cancers (Basel). 2021 Jan 7;13(2):189. doi: 10.3390/cancers13020189.

    Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.

    Marotte L, Simon S, Vignard V, Dupre E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Shaffer J, Beauvais T, Gaschet J, Scotet E, Fradin D, Jarry A, Nguyen T, Labarriere N.
    J Immunother Cancer. 2020 Jan;8(1):e000311. doi: 10.1136/jitc-2019-000311. PMID: 32001504 Free PMC article.

    Cancer Vaccines: Designing Artificial Synthetic Long Peptides to Improve Presentation of Class I and Class II T Cell Epitopes by Dendritic Cells.

    Rabu C, Rangan L, Florenceau L, Fortun, A.; Charpentier, M.; Dupré E, Paolini L, Beauvillain C, Dupel E, Latouche J.-B, Adotevi O, Labarrière N, Lang F.

    Oncoimmunology 2019, 8 (4), e1560919. doi: 10.1080/2162402X.2018.1560919

    Contact

    Contact

    Nathalie LABARRIERE

    Email

    nathalie.labarriere@univ-nantes.fr

    link linkedn team leader incit

    Website

    Nantes

    Location

    IRS2, Nantes University

    22 Boulevard Benoni Goullin

    44200 Nantes

    About us

    Created in 2022, the INCIT(Immunology and New Concepts in Immunotherapy) research unit, directed by Frédéric Altare, is based on the desire to focus thescientific expertise of the immunology and immunotherapy teams on different pathological contexts: inflammation, cancer and infectious diseases.

    Workforce

    Publications since 2016

    Doctoral students and post-docs

    Locations - Nantes and Angers